Proposing an algorithm for treatment of different manifestations of neuro-Behcet's disease

Clinical Rheumatology

Volumn 29, Issue 6, 2010, Pages 683-686

  Haghighi, Afshin Borhani ^a   Safari, Anahid ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Behcet's syndrome; Nervous system; Neuro Behcet's disease; Treatment

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; ALPHA INTERFERON; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAPSONE; ETANERCEPT; HEPARIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; WARFARIN;

ADD ON THERAPY; ALGORITHM; ARTICLE; BRAIN ATROPHY; BRAIN STEM ATROPHY; BRAIN STEM INJURY; CEREBRAL SINUS THROMBOSIS; CLINICAL FEATURE; CLINICAL STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ECONOMICS; FLU LIKE SYNDROME; HUMAN; INJECTION SITE REACTION; MENINGOENCEPHALITIS; MORNING DOSAGE; NEURO BEHCET DISEASE; NEUROLOGIC DISEASE; OCCLUSIVE CEREBROVASCULAR DISEASE; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; RECOMMENDED DRUG DOSE; SPINAL CORD DISEASE; STEM CELL TRANSPLANTATION; VEIN THROMBOSIS;

ADRENAL CORTEX HORMONES; ALGORITHMS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; BEHCET SYNDROME; BRAIN; DECISION SUPPORT TECHNIQUES; HUMANS; METHOTREXATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954424768     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1414-6     Document Type: Article

References (19)

1. Borhani Haghighi A, Pourmand R, Nikseresht AR (2005) Neuro-Behcet's disease: a review. The Neurologist 11:80-89
2. Borhani Haghighi A, Samangooei S, Ashjazadeh N et al (2006) Neurological manifestation of Behcet's disease. Saudi Med J 27 (10):1542-1546
3. Siva A, Kantarcy O, Saip S, Hamuryudan V, Altyntas A, Yazici H (1998) Neuro-Behcet syndrome: prognostic factors and survival. J Neurol 245:362
4. Hatemi G, Silman A, Bang D et al (2008) EULAR recommendations for the management of Behcet's disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 67:1656-1662
5. Borhani Haghighi A (2009) Treatment of Neuro-Behcet's disease: an update. Exp Rev Neurother 9(4):565-574
6. Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 322(5):326-328
7. Hamuryudan V, Ozyazgan Y, Hizli N et al (1997) Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum 40(4):769-774
8. Hirohata S, Suda H, Hashimoto T (1998) Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease. J Neurol Sci 159(2):181-185
9. Kikuchi H, Aramaki K, Hirohata S (2003) Low dose MTX for progressive neuro-Behcet's disease. A follow-up study for 4 years. Adv Exp Med Biol 528:575-578
10. Hamza M, Meddeb S, Mili I, Ouertani A (1992) Bolus of cyclophosphamide and methylprednisolone in uveitis in Behcet's disease. Preliminary results with the use of new criteria of evaluation. Ann Med Interne (Paris) 143(7):438-441
11. Du LT, Fain O, Wechsler B, Cochereau I et al (1990) Value of "bolus" cyclophosphamide injections in Behcet's disease. Experience of 17 cases. Presse Med 19(9):1355-1358
12. Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology (Oxford) 46(5):736-741
13. O'Duffy JD, Robertson DM, Goldstein NP (1984) Chlorambucil in the treatment of uveitis and meningoencephaliltis of Behcet's disease. Am J Med 76:75-84
14. Kotter I, Gunaydin I, Zierhut M, Stubiger N (2004) The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 33:320-335
15. Ahn JK, Lee YS, Jeon CH, Koh EM, Cha HS (2008) Treatment of venous thrombosis associated with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 27(2):201-205
16. Yazici H, Fresko I, Yurdakul S (2007) Behcet's syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 3(3):148-155
17. Siva A (2001) Vasculitis of the nervous system. J Neurol 248:451-468
18. Bank I, Weart C (1984) Dural sinus thrombosis in Behcet's disease. Arthritis Rheum 27:816-818
19. Barlas S (1999) Behcet's disease. An insight from a vascular surgeon's point of view. Acta Chir Belg 99(6):274-281